For Immediate Release Chicago, IL- May 13, 2016 – Today, Zacks Investment Ideas feature highlights Features: Post Holding (POST), Facebook (FB), Paylocity (PCTY), Ani Pharmaceuticals (ANIP) and AMN Healthcare Services (AHS). 5 Stocks with Incredible Growth Prospects It is well understood that revenue growth is a primary factor in earnings growth. As a wise investor once told me, “expense must head towards zero if a company is going to grow earnings without increasing sales.” Finding revenue growth isn’t exactly easy, but it is only part of the equation that will result in a good stock pick. Once there is revenue growth, expenses must be held somewhat constant. If you have that, then earnings will grow as well and this is what investors love to see. I screened all the Zack Rank #1 (Strong Buy) stocks for projected revenue growth of more than 35% and projected earnings growth of more than 35%. Let’s take a look at 5 of the stocks that made it to this list. Post Holding (POST) is the cereal maker that is expecting boxes to fly off the shelf this year. Analysts are calling for revenue growth of 92% and Earnings growth of 266%. Those are some huge numbers for what one might think to be a rather stable business. I looked back and didn’t find any acquisition news of merit (a small deal for $90M won’t really move the needle of a company that is reporting $1B in quarterly sales). But this underscores the point of this screen, and that is this is only the first step in a due diligence process. Book It A much more reliable name that fits on the parameters of this screen is Facebook ( FB). The social media giant is a huge grower of revenues and earnings. Analysts are calling for revenue growth of 44% and EPS growth of 88%. This type of revenue and earnings growth is just what aggressive growth investors are looking for. Another tech stock that hits the list but is a good deal smaller than FB. Paylocity ( PCTY) is based in suburban Chicago and is a cloud based provider of payroll and human capital management. PCTY is expected to post revenue growth of 41% and EPS growth of 69%. As a small cap stock this sort of growth is in line with what you would expect to see. This is also a Zacks Rank #1 (Strong Buy) as earnings estimates for the current fiscal year have moved from a loss of $0.13 to a loss of $0.08 over the 7 days. Next fiscal year estimates have also risen from a loss of $0.04 to a loss of a penny. Investors love to see losses get smaller, and if things continue to improve for PCTY, then we could see fiscal 2017 be a profitable year. 36 & 42 There are two healthcare stocks that made the list with very similar revenue and earnings growth numbers. Ani Pharmaceuticals (ANIP) is a Zacks Rank #1 (Strong Buy) and analysts are calling for 36% revenue growth and 42% growth in EPS. AMN Healthcare Services (AHS) is slated to show 42% revenue growth and 36% EPS growth. Summary This screen gives you some candidates to do more research on. You already know that earnings estimates are moving higher as they are all Zacks Rank #1 (Strong Buy) stocks, and that should be the foundation of all your research. Stocks that grow revenue and earnings at high rates have a strong likelihood of seeing share price appreciation over the coming months, but one cannot rely on the screen alone. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today. Find out what is happening in the stock market today on zacks.com. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report POST HOLDINGS (POST): Free Stock Analysis Report FACEBOOK INC-A (FB): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report AMN HLTHCR SVCS (AHS): Free Stock Analysis Report PAYLOCITY HLDG (PCTY): Free Stock Analysis Report To read this article on Zacks.com click here.